Key paediatric milestone reached in Dimerix's kidney-disease drug trial - Stockhead
Dimerix opens first paediatric site in Mexico for ACTION3 Phase 3 trial of DMX-200 to treat FSGS, with 14 more sites planned across Argentina, US, and UK. Dr Howard Trachtman joins the Medical Advisory Board to support paediatric recruitment. The trial aims to recruit 22 adolescent patients, with DMX-200 dosage confirmed for adolescents. Recruitment for the trial remains on track, with funding secured through various sources.
Reference News
Dimerix opens first paediatric site in Mexico for ACTION3 Phase 3 trial of DMX-200 to treat FSGS, with 14 more sites planned across Argentina, US, and UK. Dr Howard Trachtman joins the Medical Advisory Board to support paediatric recruitment. The trial aims to recruit 22 adolescent patients, with DMX-200 dosage confirmed for adolescents. Recruitment for the trial remains on track, with funding secured through various sources.